What is the Purpose of this Study?
This study will evaluate whether an investigational drug called BIIB122 is safe and effective in people with early-stage Parkinson’s disease (PD) who are 30-80 years old. The study also aims to learn how the body handles taking BIIB122 (tolerability), as well as how the body absorbs, processes, and removes the drug (pharmacokinetics). Researchers will examine biomarkers, which are substances that occur naturally in the body that may indicate whether a treatment is working. BIIB122 is designed to affect the activity of a specific protein in the brain and may prevent or delay the development of PD symptoms.
Eligibility
- Clinical diagnosis of PD meeting the Movement Disorder Society Clinical Diagnostic Criteria within 2 years of the Screening Visit, inclusive, and at least 30 years of age at the time of diagnosis
- Modified Hoehn and Yahr scale stages 1 to 2 (in OFF state), inclusive, at screening
- MDS-UPDRS Parts II and III (in OFF state) combined score less than or equal to (≤)40 at screening
Where can I participate?
Beverly
More about this Clinical Trial
What is the full name of this clinical trial?
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson?s Disease